Nothing Special   »   [go: up one dir, main page]

EA201301316A1 - Способ получения интермедиатов эстетрола - Google Patents

Способ получения интермедиатов эстетрола

Info

Publication number
EA201301316A1
EA201301316A1 EA201301316A EA201301316A EA201301316A1 EA 201301316 A1 EA201301316 A1 EA 201301316A1 EA 201301316 A EA201301316 A EA 201301316A EA 201301316 A EA201301316 A EA 201301316A EA 201301316 A1 EA201301316 A1 EA 201301316A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
formula
group
alkyl
reacting
Prior art date
Application number
EA201301316A
Other languages
English (en)
Other versions
EA023991B1 (ru
Inventor
Жан-Клод Паскаль
Original Assignee
Эстетра С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эстетра С.А. filed Critical Эстетра С.А.
Publication of EA201301316A1 publication Critical patent/EA201301316A1/ru
Publication of EA023991B1 publication Critical patent/EA023991B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретение относится к способу получения соединения формулы (I)включающему следующие стадии: а) взаимодействие соединения формулы (II) с ацилирующим или с силилирующим агентом с получением соединения формулы (III), где Ри Р, каждый независимо, представляет собой защитную группу, выбранную из R-Si-RRили RCO-, где Rпредставляет собой группу, выбранную из Cалкильной или С-циклоалкильной группы, каждая из которых может быть необязательно замещена одним или несколькими заместителями, независимо выбранными из фтора или Cалкильной группы; R, Rи Rкаждый независимо представляет собой группу, выбранную из Cалкильной или фенильной группы, каждая из которых может быть необязательно замещена одним или несколькими заместителями, независимо выбранными из фтора или Cалкильной группы;b) взаимодействие соединения формулы (III) в присутствии ацетата палладия или его производного с получением соединения формулы (IV); ис) взаимодействие соединения формулы (IV) с восстановителем с получением соединения формулы (I).
EA201301316A 2011-06-01 2012-06-01 Способ получения интермедиатов эстетрола EA023991B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161492300P 2011-06-01 2011-06-01
EP11168561 2011-06-01
PCT/EP2012/060447 WO2012164096A1 (en) 2011-06-01 2012-06-01 Process for the production of estetrol intermediates

Publications (2)

Publication Number Publication Date
EA201301316A1 true EA201301316A1 (ru) 2014-04-30
EA023991B1 EA023991B1 (ru) 2016-08-31

Family

ID=45003353

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301316A EA023991B1 (ru) 2011-06-01 2012-06-01 Способ получения интермедиатов эстетрола

Country Status (24)

Country Link
US (1) US11053274B2 (ru)
EP (1) EP2714710B1 (ru)
JP (2) JP6425540B2 (ru)
KR (1) KR101994805B1 (ru)
CN (2) CN107266514A (ru)
AU (1) AU2012264602B2 (ru)
BR (1) BR112013030830B1 (ru)
CA (1) CA2835981C (ru)
CY (1) CY1118150T1 (ru)
DK (1) DK2714710T3 (ru)
EA (1) EA023991B1 (ru)
ES (1) ES2579175T3 (ru)
HR (1) HRP20160692T2 (ru)
HU (1) HUE029252T2 (ru)
ME (1) ME02454B (ru)
MX (1) MX341561B (ru)
PL (1) PL2714710T3 (ru)
PT (1) PT2714710T (ru)
RS (1) RS54880B1 (ru)
SG (1) SG195118A1 (ru)
SI (1) SI2714710T1 (ru)
SM (1) SMT201600206B (ru)
WO (1) WO2012164096A1 (ru)
ZA (1) ZA201308446B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103619867B (zh) 2011-06-01 2015-12-23 埃斯特拉公司 用于产生雌四醇中间体的方法
EA023991B1 (ru) 2011-06-01 2016-08-31 Эстетра С.П.Р.Л. Способ получения интермедиатов эстетрола
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
EP2764008B1 (en) 2011-10-07 2016-08-17 Estetra S.P.R.L. Process for the production of estetrol
NO3106148T3 (ru) 2015-06-18 2018-08-11
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
HRP20211968T1 (hr) 2015-06-18 2022-03-18 Estetra Srl Orodisperzibilna jedinica za doziranje koja sadrži komponentu estetrola
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
CN105837424A (zh) * 2016-03-31 2016-08-10 常州大学 一种1-氯-3-甲基-3-丁烯-2-酮的合成方法
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
JP6935766B2 (ja) 2018-02-15 2021-09-15 日本精工株式会社 スピンドル装置
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
IT201900021879A1 (it) 2019-11-22 2021-05-22 Ind Chimica Srl PROCESSO PER LA PREPARAZIONE DI (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROLO (ESTETROLO) ED INTERMEDI DI DETTO PROCESSO
IT201900017414A1 (it) 2019-09-27 2021-03-27 Ind Chimica Srl Processo per la preparazione di (15α,16α,17β)-estra-1,3,5(10)-triene-3,15,16,17-tetrolo (Estetrolo) ed intermedi di detto processo
AU2020355615B2 (en) 2019-09-27 2023-12-14 Industriale Chimica S.R.L. Process for preparing (15α,16α,17β)-Estra-1,3,5(10)-Triene-3,15,16,17-Tetrol (Estetrol) and intermediates of said process
WO2023021026A1 (en) 2021-08-17 2023-02-23 Aspen Oss B.V. A synthetic pathway to estra-1,3,5(10)-triene-3,15a,16a,17b-tetrol
WO2023051937A1 (en) 2021-10-01 2023-04-06 Industriale Chimica S.R.L. Process for preparing (15alpha,16alpha,17 eta)-estra-1,3,5(10)-triene-3,15,16,17-tetrol (estetrol) monohydrate
WO2024160373A1 (en) 2023-02-02 2024-08-08 Industriale Chimica S.R.L. PROCESS FOR PREPARING (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRATE

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE144266C (ru)
US3138588A (en) 1962-08-24 1964-06-23 American Home Prod 17-ketals of estrone and derivatives thereof
US3177206A (en) 1963-03-07 1965-04-06 American Home Prod Selective bromination of a-ring aromatic 17-ketalized steroids
US3433785A (en) 1966-07-11 1969-03-18 Sterling Drug Inc 15,16-disubstituted aromatic steroids,intermediates and processes
US3673180A (en) 1970-06-18 1972-06-27 Merck & Co Inc 19-nor-6,6-ethylene-20-spiroxenes
US4792620A (en) 1983-10-14 1988-12-20 Bp Chemicals Limited Carbonylation catalysts
US4739078A (en) 1984-02-17 1988-04-19 The Upjohn Company Use of borohydride-salt lanthanide salt reagents for stereo selective reduction of C-15-keto prostaglandin precursors
IE60780B1 (en) 1987-01-23 1994-08-10 Akzo Nv New 11-aryl steroid derivatives
DE3710728A1 (de) * 1987-03-31 1988-10-13 Schering Ag Verfahren zur herstellung von 17(alpha)-ethinyl-17ss-hydroxy-18-methyl-4,15-estradien-3-on und die neuen zwischenprodukte fuer dieses verfahren
US5073374A (en) 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5340586A (en) 1991-04-12 1994-08-23 University Of Southern California Methods and formulations for use in treating oophorectomized women
JPH07101977A (ja) 1993-10-05 1995-04-18 Kureha Chem Ind Co Ltd ホルモン作用を軽減した新規なエストラジオール誘導体及びその増殖因子阻害剤
WO1997004752A1 (en) 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US6117446A (en) 1999-01-26 2000-09-12 Place; Virgil A. Drug dosage unit for buccal administration of steroidal active agents
TW548277B (en) 1999-07-16 2003-08-21 Akzo Nobel Nv Orally active androgens
US20020132801A1 (en) 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
DE60217324T2 (de) 2001-05-18 2007-04-26 Pantarhei Bioscience B.V. Pharmazeutische zusammensetzung für die hormonersatztherapie
WO2002094278A1 (en) 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1390042B1 (en) 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
WO2003018026A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
PT1446128E (pt) 2001-11-15 2007-03-30 Pantarhei Bioscience Bv Utilização de compostos estrogénicos combinados com compostos progestagénicos na terapia hormonal de substituição
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
HU227198B1 (en) 2001-11-27 2010-10-28 Richter Gedeon Nyrt Pharmaceutical composition for emergency contraception containing levonorgestrel
ATE341333T1 (de) 2002-02-21 2006-10-15 Schering Ag Pharmazeutische zusammensetzung, enthaltend ein oder mehrere steroide, eine oder mehrere tetrahydrofolatverbindungen und vitamin b12
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
CA2489271C (en) 2002-06-11 2011-12-06 Pantarhei Bioscience B.V. Method of treating or preventing immune mediated disorders and pharmaceutical formulation for use therein
CA2489270C (en) 2002-06-11 2012-08-07 Pantarhei Bioscience B.V. A method of treating human skin and a skin care composition for use in such a method
CA2492287C (en) 2002-07-12 2011-12-13 Pantarhei Bioscience B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
AU2003274823A1 (en) 2002-10-23 2004-05-13 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
US20060211669A1 (en) * 2002-11-08 2006-09-21 Verhaar Mark T Synthesis of estetrol via estrone derived steroids
ES2274456T3 (es) 2003-05-22 2007-05-16 Pantarhei Bioscience B.V. Uso de composiciones que comprenden un componente estrogenico para el tratamiento y la prevencion del dolor musculoesqueletico.
CN102796160A (zh) 2005-05-26 2012-11-28 索尔瓦药物有限公司 17β-HSD1和STS抑制剂
CN101228268A (zh) 2005-07-25 2008-07-23 德累斯顿工业大学 Rna扩增和/或rna标记用的rna依赖的rna聚合酶，方法及试剂盒
US20070048369A1 (en) 2005-08-26 2007-03-01 National Starch And Chemical Investment Holding Corporation Mucosal delivery tablet
EP1971344B1 (en) 2006-01-09 2010-09-22 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
US20080113953A1 (en) 2006-06-08 2008-05-15 Warner Chilcott Company, Inc. Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailability
EP2029146B8 (en) 2006-06-08 2018-02-21 Allergan Pharmaceuticals International Limited Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20070286819A1 (en) 2006-06-08 2007-12-13 Warner Chilcott Company, Inc. Methods to administer ethinyl estradiol and prodrugs thereof with improved bioavailability
GB0621926D0 (en) 2006-11-03 2006-12-13 Medlock Medical Ltd Multi directional stretch tubular bandages
RU2009117201A (ru) 2006-11-29 2011-01-10 Вайет (Us) Двухслойные таблетки на основе эстрогена/селективного модулятора эстрогенового рецептора и эстрогена/прогестина
US7867515B2 (en) 2006-12-20 2011-01-11 TEVA Woman's Health, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
EP2114412B1 (en) 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
EP2117518A2 (en) 2007-01-12 2009-11-18 Wyeth a Corporation of the State of Delaware Tablet-in-tablet compositions
CA2691654C (en) 2007-06-21 2016-06-07 Pantarhei Bioscience B.V. Treatment of meconium aspiration syndrome with estrogens
CN101778635A (zh) 2007-07-19 2010-07-14 潘塔希生物科学股份有限公司 妊娠高血压病变或胎儿生长迟缓的治疗或预防
WO2009028676A1 (ja) 2007-08-31 2009-03-05 National University Corporation Nagoya University カルボニル化合物の製造方法およびカルボニル化合物の製造に用いる酸化促進剤
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
EP2077273B1 (en) 2007-12-31 2011-09-14 Animal Technology Institute Taiwan Methods for separating casein from soluble proteins in a composition
WO2010033832A2 (en) 2008-09-19 2010-03-25 Evestra, Inc. Estriol formulations
DE102009007771B4 (de) 2009-02-05 2012-02-16 Bayer Schering Pharma Aktiengesellschaft Bukkales Applikationssystem, 17α-Estradiol enthaltend
CN102058604A (zh) 2009-11-17 2011-05-18 北京万全阳光医学技术有限公司 一种含有地诺孕素和戊酸雌二醇的药物组合物及其制备方法
US9603860B2 (en) 2010-07-28 2017-03-28 Laboratorios Leon Farma Sa Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same
EA023991B1 (ru) 2011-06-01 2016-08-31 Эстетра С.П.Р.Л. Способ получения интермедиатов эстетрола
CN103619867B (zh) 2011-06-01 2015-12-23 埃斯特拉公司 用于产生雌四醇中间体的方法
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
RU2627111C2 (ru) 2011-07-19 2017-08-03 Пантархей Байосайенс Б.В. Таблетка, содержащая дегидроэпиандростерон (дгэа)
BR112014003113A2 (pt) 2011-08-11 2017-03-14 Estetra Sprl método de contracepção de emergência em uma fêmea mamífero
KR20140061438A (ko) 2011-09-16 2014-05-21 훼링 비.브이. 속용성 약학 조성물
EP2764008B1 (en) 2011-10-07 2016-08-17 Estetra S.P.R.L. Process for the production of estetrol
US9808470B2 (en) 2012-04-19 2017-11-07 Universite De Liege Estrogenic components for use in the treatment of neurological disorders
EP2653163A1 (en) 2012-04-19 2013-10-23 Université de Liège Estrogenic components for use in the treatment of neurological disorders
WO2014159377A1 (en) 2013-03-14 2014-10-02 Teva Women's Health, Inc. Compositions containing tanaproget and natural estrogens
WO2015040051A1 (en) 2013-09-18 2015-03-26 Crystal Pharma, S.A.U. Process for the preparation of estetrol
CN105979935B (zh) 2013-12-12 2019-07-26 多内斯塔生物科学股份有限公司 包含雌四醇组分的口崩固体剂量单位
NO3106148T3 (ru) 2015-06-18 2018-08-11
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
ES2877186T3 (es) 2015-06-18 2021-11-16 Estetra Sprl Comprimido orodispersable que contiene estetrol
HRP20211968T1 (hr) 2015-06-18 2022-03-18 Estetra Srl Orodisperzibilna jedinica za doziranje koja sadrži komponentu estetrola

Also Published As

Publication number Publication date
EP2714710B1 (en) 2016-04-06
CN103703014A (zh) 2014-04-02
EA023991B1 (ru) 2016-08-31
BR112013030830A2 (pt) 2016-08-30
HRP20160692T1 (hr) 2016-08-12
MX2013014045A (es) 2014-08-22
KR101994805B1 (ko) 2019-07-01
CY1118150T1 (el) 2017-06-28
CA2835981A1 (en) 2012-12-06
MX341561B (es) 2016-08-25
NZ617613A (en) 2015-12-24
HRP20160692T2 (hr) 2016-09-23
US11053274B2 (en) 2021-07-06
HUE029252T2 (en) 2017-02-28
JP6425540B2 (ja) 2018-11-21
JP6479912B2 (ja) 2019-03-06
PL2714710T3 (pl) 2017-03-31
ZA201308446B (en) 2016-08-31
PT2714710T (pt) 2016-07-12
ME02454B (me) 2016-09-20
AU2012264602B2 (en) 2017-03-09
CA2835981C (en) 2018-07-24
DK2714710T3 (en) 2016-06-27
KR20140036205A (ko) 2014-03-25
CN107266514A (zh) 2017-10-20
SI2714710T1 (sl) 2016-08-31
JP2014518199A (ja) 2014-07-28
WO2012164096A1 (en) 2012-12-06
SG195118A1 (en) 2013-12-30
US20140107358A1 (en) 2014-04-17
JP2018024673A (ja) 2018-02-15
BR112013030830B1 (pt) 2019-12-03
RS54880B1 (sr) 2016-10-31
EP2714710A1 (en) 2014-04-09
SMT201600206B (it) 2016-08-31
ES2579175T3 (es) 2016-08-05

Similar Documents

Publication Publication Date Title
EA201301316A1 (ru) Способ получения интермедиатов эстетрола
EA201391180A1 (ru) Способ получения оптически активных производных дигидробензофурана
EA201500173A1 (ru) Фунгицидные композиции
EA201591503A1 (ru) Производные нафтиридина, полезные в качестве антагонистов альфа-v-бета-6 интегрина
UA111626C2 (uk) Похідні дигідрохінолін-2-ону
EA201301315A1 (ru) Способ получения промежуточных соединений эстетрола
MX351639B (es) Metodo para producir un agente para el control de plagas.
IN2014DN00144A (ru)
EA201390235A1 (ru) Способ получения карбонильных соединений
NZ707276A (en) Compounds useful in the synthesis of benzamide compounds
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
CR20130597A (es) Isoxazolinas como agentes terapèuticos
EA201490998A1 (ru) Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)-уксусной кислоты
IN2014MN00850A (ru)
MX369470B (es) Medios y método para el tratamiento de tumores sólidos.
EA201291235A1 (ru) Новые способы
CY1111873T1 (el) Νεα μεθοδος παραλαβης της κρυσταλλικης μορφης v της αγομελατινης
MX2015005592A (es) Método de preparación de los compuestos de ceramidas de alfa-galactosilo.
EA201300792A1 (ru) Химические соединения
BR112013024361A2 (pt) novos compostos de azaspirodecanona como inibidores de hsl
CY1120784T1 (el) Νεα κρυσταλλικη μορφη
EA201300794A1 (ru) Новый способ синтеза агомелатина
EA201490019A1 (ru) Способ получения производных имидазола
MX369283B (es) Preparacion de 2-amino-5-ciano-n, 3-dimetilbenzamida.
EA201300650A1 (ru) Разделение энантиомеров производных триазина с использованием винной кислоты

Legal Events

Date Code Title Description
PD1A Registration of transfer to a eurasian application by order of succession in title